PAVmed Financial Results
PAVmed reported preliminary Q3 2026 financial results, highlighted by its subsidiary Lucid Diagnostics securing nationwide Medicare reimbursement for the EsoGuard test. The company reported $1.2 million in revenue for the quarter and noted that October saw record test volume of over 1,800 tests.
- Term
- Q3 2026
“We’re very encouraged by developments across the PAVmed portfolio. Lucid securing Medicare reimbursement for EsoGuard is a critical and transformational milestone. As Lucid’s largest common shareholder, PAVmed stands to benefit directly from Lucid’s substantial near-term revenue opportunity. Veris continues to grow enrollment at Ohio State while advancing its implantable monitor toward FDA submission. We are also now actively engaged with FDA on both PortIO and Octeris. We believe this progress puts PAVmed in a strong position to create real long-term shareholder value.”
Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer